StocksMedium•1 October 2026•
1 min read
Regeneron Shares Decline After Ovarian Cancer Trial Results
Key Facts
1Regeneron Pharmaceuticals shares declined following the release of initial Phase 1/2 trial results for its experimental therapy ubamatamab.
2The stock decline occurred despite earlier gains driven by an expanded collaboration with its partner Sanofi.
Regeneron Pharmaceuticals shares declined following the release of initial Phase 1/2 trial results for ubamatamab, an experimental therapy targeting ovarian cancer. Seeking Alpha reported that the stock's reversal occurred despite earlier gains driven by an expanded collaboration with its partner Sanofi.
REGN closed at $758.27 on September 30, 2026, after reaching a day high of $763.72 and a low of $742.94. Meanwhile, shares of partner Sanofi (SNYNF) closed at $80.76 on September 30, 2026, as the market assessed the latest clinical data from the biotechnology firm.